Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Oct
02
Today In Oncology
Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence
Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo